Table 2. Few literature review of MRI findings in JE from India.
| Parameters | Kalita et al, 2003 31 | Basumatary et al, 2013 18 | Borah et al, 2015 29 | Agarwal et al, 2018 30 |
Our study | ||||
|---|---|---|---|---|---|---|---|---|---|
| Abbreviations: JE, Japanese encephalitis; MRI, magnetic resonance imaging; NCC, neurocysticercosis. | |||||||||
| No of patients underwent MRI | Pediatric JE ( n = 24) | Adult JE ( n = 32) | Pediatric JE ( n = 23) | Adult JE ( n = 34) | Pediatric JE ( n = 21) | Pediatric JE ( n = 25) | Combined pediatric and adult JE ( n = 54) |
Pediatric JE ( n = 32) | Adult JE ( n = 22) |
| Mean age | – | – | – | – | – | 12.9 ± 1.9 (SD) y | 9.7 ± 5.4 (SD) y | 42.2 ± 1.5 (SD) y | |
| Thalamic involvement | 21/24 (87.5%) | 28/32 (87.5%) | 13/23 (56.5%) | 23/34 (67.7%) | 14/21 (66.7%) | 16/25(64%) | 53/54 (98.1%) | 31/32 (96.9%) | 22/22 (100%) |
| Unilateral | – | – | 38.1% | – | 1/54 (1.9%) | 1/32 (3.1%) | – | ||
| Bilateral symmetrical | – | – | 33.3% | – | 4/54 (7.4%) | 2/32 (6.2%) | 2/22 (9.1%) | ||
| Bilateral asymmetrical | – | – | 28.6% | – | 48/54 (88.9%) | 28/32 (87.5%) | 20/22 (90.9%) | ||
| Midbrain (substantia nigra) involvement | 11/24 (45.8%) | 9/32 (28.1%) | 10/23 (43.5%) | 7/34 (20.6%) | 11/21 (52.4%) | 12/25(48%) | 44/54 (81.5%) | 25/32 (78.1%) | 19/22 (86.4%) |
| Bilateral symmetrical | – | – | – | 12/54 (22.2%) | 7/32 (21.9%) | 5/22 (22.2%) | |||
| Bilateral asymmetrical | – | – | – | 30/54 (59.3%) | 18/32 (56.2%) | 14/22 (63.6%) | |||
| Basal ganglia involvement | 13/24 (54.2%) | 13/32 (40.6%) | 6/23 (26%) | 10/34 (29.4%) | – | 3/25 (12%) | 33/54 (61.1%) | 16/32 (50%) | 16/22 (72.7%) |
| Caudate nucleus involvement | – | – | – | 22/54 (40.7%) | 11/32 (34.4%) | 11/22 (50%) | |||
| Unilateral | – | 6/54 (11.1%) | 4/32 (12.5%) | 2/22 (9.1%) | |||||
| Bilateral symmetrical | – | 8/54 (14.8%) | 4/32 (12.5%) | 4/22 (18.2%) | |||||
| Bilateral asymmetrical | 8/54 (14.8%) | 3/32 (9.4%) | 5/22 (22.7%) | ||||||
| Lentiform nucleus involvement | – | – | – | 29/54 (53.7%) | 15/32 (46.9%) | 14/22 (63.6%) | |||
| Unilateral | – | 10/54 (18.5%) | 5/32 (15.6%) | 5/22 (22.7%) | |||||
| Bilateral symmetrical | – | 4/54 (7.4%) | 3/32 (9.4%) | 1/22 (4.5%) | |||||
| Bilateral asymmetrical | – | 15/54 (27.8%) | 7/32 (21.9%) | 8/22 (36.4%) | |||||
| Hippocampus involvement | – | – | 2/23 (8.7%) | 8/34 (23.5%) | 1/21 (5) | – | 14/54 (26%) | 7/32 (21.9%) | 7/22 (31.8%) |
| Unilateral | – | 9/54 (16.7%) | 4/32 (12.5%) | 5/22 (22.7%) | |||||
| Bilateral | – | 5/54 (9.3%) | 3/32 (9.4%) | 2/22 (9.1%) | |||||
| Insular cortex involvement | – | – | 1/23 (4.3%) | – | 2/21 (9.5%) | – | 2/54 (3.7%) | 1/32 (3.1%) | 1/22 (4.5%) |
| Cerebral cortex involvement | 6/24 (25%) | 7/32 (21.9%) | 9/23 (39.1%) | 7/34 (20.6%) | 6/21 (28.6%) | 6/25 (24%) | 21/54 (38.9%) | 14/32 (43.7%) | 7/22 (31.8%) |
| Pontine involvement | 2/24 (8.3%) | 3/32 (9.3%) | 5/23 (21.7%) | 5/34 (14.7%) | – | – | 5/54 (9.3%) | 3/32 (9.4%) | 2/22 (9.1%) |
| Medulla involvement | – | – | – | – | – | – | 3/54 (5.6%) | 2/32 (6.2%) | 1/22 (4.5%) |
| Coinfection with NCC | 3/24 (12.5%) | 3/23 (13%) | 4/34 (11.8%) | 10/21 (47.6%) | – | 12/54 (22.2%) | 7/32 (21.8%) | 5/22 (22.7%) | |